![]() |
市场调查报告书
商品编码
1801256
2025 年至 2033 年质谱市场规模、份额、趋势及按技术、应用和地区分類的预测Mass Spectrometry Market Size, Share, Trends and Forecast by Technology, Application, and Region, 2025-2033 |
2024 年全球质谱市场规模为 69.3 亿美元。预计到 2033 年,该市场将达到 117.2 亿美元,2025-2033 年期间的复合年增长率为 5.72%。北美目前占据市场主导地位,2024 年市占率约 41.7%。製药、生物技术和食品安全产业对精确、快速分析方法的需求推动了质谱市场的发展。此外,药物开发和发现的投资增加,加上慢性病发病率的上升,加速了质谱在蛋白质体学、代谢组学和临床诊断的应用。此外,混合光谱技术和自动化程度的提高,提高了仪器功能,进一步扩大了质谱市场份额。
市场主要受高解析度仪器和增强电离技术的持续进步影响,这些技术正在推动其在各个领域的广泛应用。此外,对环境污染和微量检测的担忧也加剧了食品检测和水质监测领域的部署。 2025年1月发表的一项研究强调了质谱技术(包括气相层析-质谱联用、液相层析-质谱联用/质谱联用和高解析度混合系统)在监测水、土壤和空气基质中微量新兴环境污染物方面的关键作用。研究报告指出,水中药物残留的检测极限低至1.13-5.45 ng L-1,并强调高解析度平台能够即时检测挥发性有机化合物和非标靶筛选能力。此外,不断扩展的药物研发管线和生物製药研究的激增需要精确的分子表征,这进一步支撑了市场需求。
在美国,市场受到个人化医疗和基因研究日益增长的重视所驱动,这增加了对详细分子分析工具的需求。此外,新兴的质谱市场趋势之一是联邦政府为生物医学和临床研究提供大量资金,以维持重大设备升级。根据产业报告,美国国立卫生研究院 (NIH) 每年投资超过 470 亿美元,使其成为全球最大的健康、医学和行为研究公共资金来源。此外,食品标籤和农药残留的严格规定推动了农业和食品检测实验室的采用。此外,先进法医协议的发展和国土安全措施的加强促使各机构购买精确的检测设备。此外,将质谱技术整合到代谢组学和脂质组学工作流程中可以增强研究深度。此外,领先製造商的强大影响力和便捷的技术支援推动了全国范围内对实验室的持续投资。
技术进步
持续的技术进步极大地促进了市场的成长。更高的灵敏度、更高的准确度和更快的吞吐量等尖端改进,使这些仪器在现代实验室中不可或缺。此外,技术进步正在扩展质谱仪器的功能,使其能够分析日益复杂的样品。此外,高解析度质谱和串联质谱等最新创新技术提供了前所未有的细节和分析深度,也支撑了市场的成长。此外,即时监控功能的加入,允许即时资料收集和解读,也增强了质谱市场的成长。此外,这些设备的小型化也促成了可用于现场分析的便携式设备的诞生,从而有利于市场的发展。因此,2025年3月,908 Devices公司从乌克兰卫生部获得了一份价值170万美元的订单,订购MX908手持式质谱仪,用于检测战后环境测试中的危险物质和爆炸物,这凸显了对便携式解决方案日益增长的需求。
严格的品质管制监管政策
製药和食品安全等行业对品质控制的监管要求正在推动市场扩张。监管机构推出的严格标准促使企业依赖质谱法,因为其在检测杂质、确保产品品质和验证製程方面具有高度的准确性和灵敏度。此外,质谱法还能确保化合物符合纯度标准,并能在极低浓度下检测到污染物。因此,布鲁克在2025年4月收购了RECIPE的多数股权。 RECIPE是一家总部位于慕尼黑的临床质谱试剂盒供应商,拥有60名员工,年收入1500万美元,致力于推进高通量「无铬」ClinDART TDM检测技术。此外,食品业广泛应用技术以确保不含农药、毒素和其他污染物,也有利于市场成长。此外,这些监管强制要求使质谱法不仅是一种选择,更成为产品开发和製造过程中品质保证的必需品。
个人化医疗日益受到关注
对个人化医疗的日益重视是另一个对质谱市场前景产生正面影响的关键因素。一份产业报告指出,美国食品药物管理局 (FDA) 批准了 300 多种个人化药物,其中约 25% 的新药与生物标记资料相关,个人化策略目前占主要製药产品线的 40% 以上。医疗保健正日益针对个别患者进行量身定制,这导致对详细的分子和遗传资讯的需求也越来越高。质谱技术能够在分子层面上分析生物标记、代谢物和蛋白质,从而在蛋白质体学和基因组学研究中发挥重要作用。这些见解对于了解个人健康状况、预测疾病易感性并相应地制定治疗方案至关重要。此外,个人化医疗的兴起正推动医疗保健提供者和研究机构投资质谱技术,以满足对精确的患者特定资料的需求。因此,对个人化医疗保健的关注不仅推动了质谱技术在现有市场中的应用,也开创了其进入医学科学新领域的先河。
The global mass spectrometry market size was valued at USD 6.93 Billion in 2024. The market is projected to reach USD 11.72 Billion by 2033, exhibiting a CAGR of 5.72% during 2025-2033. North America currently dominates the market, holding a significant market share of around 41.7% in 2024. The market is fueled by the demand for precise and fast analytical methods in the pharmaceutical, biotechnology, and food safety industries. Moreover, increased investments in drug development and discovery, combined with the rising incidences of chronic diseases, are accelerating the adoption of mass spectrometry for proteomics, metabolomics, and clinical diagnostics. Furthermore, improvements in hybrid spectrometry technology and automation are improving instrument functionality, further augmenting the mass spectrometry market share.
The market is majorly influenced by the continuous advancements in high-resolution instrumentation and enhanced ionization techniques, which are encouraging wider use across sectors. Moreover, concerns over environmental contamination and trace-level detection have intensified deployment in food testing and water quality monitoring. A research study published in January 2025 highlights the pivotal role of mass spectrometry, including GC MS, LC MS/MS, and high resolution hybrid systems, in monitoring trace levels of emerging environmental contaminants across water, soil, and air matrices. It reports detection limits as low as 1.13-5.45 ng L-1 for pharmaceutical residues in water and emphasizes real time detection of volatile organic compounds and non targeted screening capabilities enabled by high resolution platforms. Also, expanding pharmaceutical pipelines and the surge in biopharmaceutical research require precise molecular characterization, further supporting demand.
In the United States, the market is driven by the growing emphasis on personalized medicine and genetic studies, which increases the requirement for detailed molecular profiling tools. Furthermore, one of the emerging mass spectrometry market trends is the substantial federal funding for biomedical and clinical research sustaining significant equipment upgrades. As per industry reports, the National Institutes of Health (NIH) invests over USD 47 Billion each year, making it the world's biggest public source of funding for research in health, medicine, and behavior. Besides, strict regulations for food labeling and pesticide residue drive adoption among agricultural and food testing labs. In addition, the development of advanced forensic protocols and heightened homeland security measures pushes agencies to acquire precise detection equipment. Also, integration of mass spectrometry into metabolomics and lipidomics workflows enhances research depth. Additionally, the robust presence of leading manufacturers and accessible technical support boosts continuous laboratory investments nationwide.
Technological Advancements
Continuous technological advancements are significantly contributing to the growth of the market. Cutting-edge improvements, such as higher sensitivity, better accuracy, and rapid throughput, are making these instruments indispensable in modern laboratories. Furthermore, technological progress is expanding the capabilities of mass spectrometry instruments to include the analysis of increasingly complex samples. Additionally, recent innovations like high-resolution mass spectrometry and tandem mass spectrometry that are providing unprecedented levels of detail and analytical depth are supporting the market growth. Moreover, the incorporation of real-time monitoring capabilities, allowing immediate data collection and interpretation, is strengthening the mass spectrometry market growth. In addition, the miniaturization of these devices is leading to the creation of portable units that can be employed for on-site analysis, thereby favoring the market development. As such, in March 2025, 908 Devices received a USD 1.7 Million order from Ukraine's Ministry of Health for MX908 handheld mass spectrometers to detect hazardous substances and explosives for post-war environmental testing, highlighting the growing demand for portable solutions.
Strict Regulatory Policies for Quality Control
Regulatory requirements for quality control in industries, such as pharmaceuticals and food safety, are propelling the market expansion. The introduction of stringent standards by regulatory agencies is prompting companies to rely on mass spectrometry for its high degree of accuracy and sensitivity in detecting impurities, ensuring product quality, and validating processes. In addition, mass spectrometry ensures that compounds meet purity standards and that contaminants are detected at extremely low concentrations. Accordingly, in April 2025, Bruker acquired a majority stake in RECIPE, a Munich-based clinical MS kit provider with 60 employees and USD 15 Million revenue, advancing high-throughput 'chrom-free' ClinDART TDM assays. Furthermore, the widespread technology utilization in the food industry to ensure the absence of pesticides, toxins, and other contaminants is favoring the market growth. Moreover, these regulatory compulsions make mass spectrometry not just an option but a necessity for quality assurance in product development and manufacturing processes.
Growing Focus on Personalized Medicine
The growing emphasis on personalized medicine is another pivotal factor positively impacting the mass spectrometry market outlook. An industry report noted that the FDA approved over 300 personalized medicines, with about 25% of new drugs linked to biomarker data, and personalized strategies now make up over 40% of major pharma pipelines. Healthcare is becoming increasingly tailored to individual patients, resulting in a higher demand for detailed molecular and genetic information. Mass spectrometry provides the capability to analyze biomarkers, metabolites, and proteins at a molecular level, thereby playing a significant role in proteomics and genomics research. These insights are crucial for understanding individual health profiles, predicting disease susceptibility, and tailoring treatments accordingly. Furthermore, the rise in personalized medicine is pushing healthcare providers and research institutions to invest in mass spectrometry technologies to keep up with the demand for precise, patient-specific data. As a result, the focus on personalized healthcare is not only boosting the application of mass spectrometry in existing markets but is also pioneering its entry into new avenues of medical science.
Triple quadrupole (tandem) leads the market with around 37.5% of market share in 2024.Triple quadrupole systems offer high sensitivity and selectivity, making them ideal for detecting low-abundance analytes in complex samples. Furthermore, they are versatile and can be applied to various fields, such as proteomics, metabolomics, pharmaceuticals, and environmental analysis. This multi-disciplinary application range contributes to their widespread adoption. Besides this, triple quadrupole mass spectrometers excel in quantitative measurements, as they provide excellent repeatability and accuracy, which are crucial in sectors like drug development and diagnostics. Additionally, these systems are often compatible with various ionization techniques and chromatography systems, allowing for broader applications and easier integration into existing workflows. Moreover, triple quadrupole meets or exceeds the stringent regulations and quality standards required in many industries, which makes them a safer investment for compliance-conscious organizations.
Pharmaceuticals lead the market in 2024. Pharmaceuticals are governed by strict regulatory standards. In line with this, mass spectrometry is invaluable for quality control and compliance, ensuring that pharmaceutical products meet these rigorous benchmarks. Furthermore, mass spectrometry is critical in the various stages of drug discovery, including target identification, screening, and pharmacokinetics. It provides accurate and precise data that aid researchers in the identification and quantification of compounds, thereby accelerating the time-to-market for new drugs. Besides this, mass spectrometry offers the high sensitivity and specificity required for proteomic and genomic studies, thereby driving its adoption in the pharmaceutical sector. Additionally, it is extensively used in metabolomics to identify and quantify metabolites, thus offering valuable insights into drug metabolism. Moreover, mass spectrometry is routinely used for quality control and batch-to-batch verification of raw materials, intermediates, and finished products.
In 2024, North America accounted for the largest market share of over 41.7%. North America hosts some of the world's leading research institutions and laboratories, which contributes to a high demand for mass spectrometry equipment for advanced research. Additionally, various government agencies are offering substantial grants and funding options for research and development (R&D) activities, including those that require mass spectrometry, thus fostering a favorable environment for market growth. Besides this, North America is the headquarters for numerous companies that are market leaders in the mass spectrometry segment. Moreover, the region is at the forefront of technological innovation in advanced mass spectrometry techniques like time-of-flight (TOF) and orbitrap. In addition to this, the presence of a robust healthcare system, coupled with the focus on precision medicine and diagnostics in the region, is further boosting the market growth.
United States Mass Spectrometry Market Analysis
In 2024, the United States holds a substantial share of around 87.50% of the mass spectrometry market share in North America. The market in the United States is primarily driven by strong investments in biomedical research, which are expanding applications in precision medicine and personalized healthcare. According to the World Health Organization (WHO), approximately 88% of all biomedical research grants, amounting to nearly USD 33 Billion, were awarded to organizations based in the United States. In line with this, the rapid integration of high-resolution mass spectrometry in clinical diagnostics, which facilitates the early detection of diseases and therapeutic drug monitoring, is driving market growth. The rise in biopharmaceutical manufacturing is further propelling demand for advanced analytical systems to ensure quality control and regulatory compliance. Similarly, increasing government fundings for environmental monitoring, which encourages the widespread deployment of pollutant and toxin analysis, is fostering market expansion. The rising focus on food safety testing for contaminants and residues is driving additional market appeal. Additionally, the expansion of forensic and crime laboratories is stimulating the use of portable and high-throughput mass spectrometry solutions. Apart from this, continuous innovations in hybrid and tandem systems, which reinforces U.S. leadership in analytical research capabilities, is expanding the market scope.
Europe Mass Spectrometry Market Analysis
The European market is experiencing growth due to strong investments in life sciences infrastructure, supported by national and EU-level funding initiatives. In accordance with this, the growing demand for advanced analytical techniques to meet stringent EU environmental regulations is driving market expansion. Similarly, rising investment in precision medicine and oncology programs, transforming the clinical diagnostics landscape, is expanding market reach. As such, in 2024, Berlin-based AI company Aignostics raised €31.4 million in Series B funding to enhance precision medicine through AI-driven pathology insights. The round was led by ATHOS, with investments from Mayo Clinic, HTGF, and other existing investors. The heightened need for food authenticity testing and contaminant traceability driving the deployment of high-resolution systems is supporting market demand. Additionally, the emerging trend of cross-border research collaborations, which encourages the adoption of interoperable, standardized analytical platforms, is stimulating market accessibility. The rapid expansion of biopharmaceutical pipelines and biologics manufacturing hubs is driving a significant increase in the market appeal. Besides this, Europe's expanding network of accredited testing facilities and the emphasis on laboratory automation are further providing an impetus to the regional market.
Asia Pacific Mass Spectrometry Market Analysis
The mass spectrometry market in the Asia Pacific is largely driven by rising government investments in precision medicine and genomic research. Furthermore, the growth of pharmaceutical manufacturing hubs in India and China, which drives demand for high-performance analytical instruments, is propelling market expansion. Similarly, increased collaborations between academic institutions and biotech companies, which foster innovation in biomarker discovery and proteomics, are strengthening market demand. The heightened adoption of stricter environmental monitoring standards is promoting the deployment of highly sensitive detection technologies. Additionally, the region's intensified focus on food safety testing is accelerating the use of mass spectrometry in the agro-food sector. Moreover, increasing funding for research and development is promoting the adoption of advanced mass spectrometry solutions in Asia Pacific healthcare and public health laboratories. Accordingly, in 2024, the National Natural Science Foundation of China (NSFC) and the U.S. NSF funded joint projects on infectious disease ecology and evolution, offering up to RMB 4.5 Million (about USD 630,000) per research project and RMB 1 Million (about USD 140,000) per exchange project, encouraging new international networks.
Latin America Mass Spectrometry Market Analysis
In Latin America, the market is growing due to increasing government investments in public health surveillance and advanced disease diagnostics. Similarly, the expansion of precision medicine programs is driving demand for high-resolution analytical tools to support the discovery of biomarkers and the development of targeted therapies. As such, in April 2025, MGI expanded its partnership with Brazil's Fiocruz to boost epidemiological surveillance and personalized medicine, equipping UNADIG's labs with advanced sequencers to process 2,000 genetic samples weekly and 29,000 clinical samples daily. The increasing emphasis on environmental monitoring and food safety regulations is driving the deployment of advanced mass spectrometry instruments for the detection of pollutants and quality control. Furthermore, expanding collaborations between local institutions and global pharmaceutical companies are driving technology transfer, advancing innovation, and broadening the market scope.
Middle East and Africa Mass Spectrometry Market Analysis
The mass spectrometry market in the Middle East and Africa is expanding due to increasing investments in healthcare infrastructure and advanced diagnostic capabilities across leading GCC nations. Furthermore, a heightened regulatory focus on food safety and environmental monitoring is driving the adoption of high-performance mass spectrometry in laboratories and testing centers. Similarly, collaborative research partnerships between regional universities and global analytical technology providers are supporting knowledge transfer and developing local expertise. Moreover, the region's growing pharmaceutical manufacturing sector is driving demand for precise analytical tools to ensure quality control, drug safety, and compliance with international standards, thereby providing an impetus to the market. Accordingly, in May 2025, Julphar announced a five-year investment plan of AED 300 Million (about USD 81 Million) to expand manufacturing, enhance technology, and encourage UAE pharmaceutical exports to over 40 global markets.
The competition in the market is intense, driven by continuous technological innovations and the growing requirement for accurate, dependable analytical solutions in a variety of industries. Firms in this market concentrate on creating hybrid platforms, miniaturized instruments, and user-friendly software interfaces to improve their competitive advantage. In addition, rigorous regulatory standards and increasing demand for sophisticated analytical capability across pharmaceutical development, food safety, and environmental testing drive ongoing investment in research and development (R&D). Besides, end users now place significant value on integrated systems that deliver accurate, complex analyses with minimal manual intervention, resulting in a greater emphasis on automation and ease of operation. Also, the demand for portable and high-throughput instruments is rising, driven by laboratories seeking to improve turnaround times and cost efficiency. According to the mass spectrometry market forecast, expanding applications in personalized medicine, proteomics, and metabolomics are expected to further accelerate the need for sophisticated mass spectrometry systems.